Law360, New York (June 15, 2010, 7:18 PM ET) -- Allergan Inc. has accused Apotex Inc. of infringing four patents for Combigan, marking the drugmaker's latest attempt to block a generic version of the glaucoma treatment from hitting the market.
Allergen filed suit Tuesday in the U.S. District Court for the Eastern District of Texas, claiming that the Canadian generics maker and its U.S. subsidiary Apotex Corp. infringed patents covering Combigan by submitting an abbreviated new drug application to manufacture their own version of brimonidine tartrate/ timolol maleate ophthalmic solution.
“The commercial manufacture, use, offer for...
Allergan Goes After Apotex Over Combigan ANDA
To view the full article, take a free trial now.
